Hereditary diffuse gastric cancer and lost cell polarity: A short path to cancer

Future Oncology

Volumn 4, Issue 2, 2008, Pages 229-239

  Humar, Bostjan ^a   Guilford, Parry ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Chemoprevention; DNA methylation; E cadherin; Epigenetic therapy; HDAC inhibitors; Hereditary diffuse gastric cancer; Hypoxia; Polarity; Stem cells

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA CATENIN; ANTINEOPLASTIC AGENT; APICIDIN; AZACITIDINE; CYTOTOXIC AGENT; DNA DEMETHYLATING AGENT; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; UVOMORULIN; VALPROIC ACID; VORINOSTAT; ZEBULARINE; CADHERIN; CDH1 PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER STEM CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL DIVISION; CELL POLARITY; CELL RENEWAL; CELL SUBPOPULATION; CONCENTRATION RESPONSE; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; EPIGENETICS; FAMILIAL CANCER; GENE DISRUPTION; GENE LOSS; GENE MUTATION; GENE SILENCING; HUMAN; IMMUNOMODULATION; LAMINA PROPRIA; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SIGNET RING CARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS; TARGET CELL; TERATOGENICITY; ALLELE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; PATHOPHYSIOLOGY; STOMACH TUMOR;

ALLELES; CADHERINS; CELL ADHESION; CELL POLARITY; DOWN-REGULATION; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; STOMACH NEOPLASMS;

EID: 43049105830     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.2.229     Document Type: Review

References (85)

1. Guilford P, Hopkins J, Harraway J et al.: E-cadherin germline mutations in familial gastric cancer. Nature 392, 402-405 (1998).
2. Perez-Moreno M, Jamora C, Fuchs E: Sticky business: orchestrating cellular signals at adherens junctions. Cell 112, 535-548 (2003).
3. Chan JK, Wong CS: Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv. Anat. Pathol. 8, 165-172 (2001).
4. Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG: Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Cut 53, 814-820 (2004).
5. Huntsman DG, Carneiro F, Lewis FR et al.: Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N. Engl. J. Med. 344, 1904-1909 (2001).
6. Chun YS, Lindor NM, Smyrk TC et al.: Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92, 181-187 (2001).
7. Humar B, Fukuzawa R, Blair V et al.: Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res. 67, 2480-2489 (2007).
8. Karam SM, Straiton T, Hassan WM, Leblond CP: Defining epithelial cell progenitors in the human oxyntic mucosa. Stem Cells 21, 322-336 (2003).
9. Carneiro F, Huntsman DG, Smyrk TC et al.: Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J. Pathol. 203, 681-687 (2004).
10. Grady WM, Willis J, Guilford PJ et al.: Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat. Genet. 26, 16-17 (2000).
11. Corso G, Roviello F, Paredes J et al.: Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. Eur. J. Surg. Oncol. 33, 1061-1067 (2007).
12. Ushijima T: Epigenetic field for cancerization. J. Biochem. Mol. Biol. 40, 142-150 (2007).
13. Roth SY, Denu JM, Allis CD: Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120 (2001).
14. Peinado H, Ballestar E, Esteller M, Cano A: Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/ HDAC2 complex. Mol. Cell. Biol. 24, 306-319 (2004).
15. Oliveira C, de Bruin J, Nabais S et al.: Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 23, 2236-2240 (2004).
16. Bush KT, Tsukamoto T, Nigam SK: Selective degradation of E-cadherin and dissolution of E-cadherin -catenin complexes in epithelial ischemia. Am. J. Physiol. Renal Physiol. 278, F847-F852 (2000).
17. Covington MD, Burghardt RC, Parrish AR: Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am. J. Physiol. Renal Physiol. 290, F43-F51 (2006).
18. le Borgne R, Bellaiche Y, Schweisguth F: Drosophila E-cadherin regulates the orientation of asymmetric cell division in the sensory organ lineage. Curr. Biol. 12, 95-104 (2002).
19. Johnson MH, McConnell IM: Lineage allocation and cell polarity during mouse embryogenesis. Semin. Cell Dev. Biol. 15, 583-597 (2004).
20. Vleminckx K, Vakaet L, Mareel M, Fiers W, van Roy F: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107-119 (1991).
21. Clark SJ, Melki J: DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21, 5380-5387 (2002).
22. Clark SJ: Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum. Mol. Genet. 16(Spec. No. 1), R88-R95 (2007).
23. Mutskov V, Felsenfeld G: Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J. 23, 138-149 (2004).
24. Mummaneni P, Yates P, Simpson J, Rose J, Turker MS: The primary function of a redundant Sp1 binding site in the mouse aprt gene promoter is to block epigenetic gene inactivation. Nucleic Acids Res. 26, 5163-5169 (1998).
25. Tagoh H, Schebesta A, Lefevre P et al.: Epigenetic silencing of the c-fms locus during B-lymphopoiesis occurs in discrete steps and is reversible, EMBO J. 23, 4275-4285 (2004).
26. Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS: Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasla, and chronic inflammation. Am. J. Pathol. 163, 1551-1556 (2003).
27. Hanby AM, Chinery R, Poulsom R, P14yford RJ, Pignatelli M: Downregulation of E-cadherin in the reparative epithelium of the human gastrointestinal tract. Am. J. Pathol. 148, 723-729 (1996).
28. Demetter P, de Vos M, van Damme N et al.: Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. Am. J. Clin. Pathol. 114, 364-370 (2000).
29. Dogan A, Wang ZD, Spencer J: E-cadherin expression in intestinal epithelium. J. Clin. Pathol. 48, 143-146 (1995).
30. Terres AM, Pajares JM. O'Toole D, Ahern S, Kelleher D: H pylori infection is associated with downregulation of E-cadherin, a molecule involved in epithelial cell adhesion and proliferation control. J. Clin. Pathol. 51, 410-412 (1998).
31. Krishnamachary B, Zagzag D, Nagasawa H et al.: Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 66, 2725-2731 (2006).
32. Imai T, Horiuchi A, Wang C et al.: Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163, 1437-1447 (2003).
33. Maxwell PH, Wiesener MS, Chang GW et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen dependent proteolysis. Nature 399, 271-275 (1999).
34. Mandriota SJ, Turner KJ, Davies DR et al.: HIF activation-identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459-468 (2002).
35. Esteban MA, Tran MG. Harten SK et al.: Regulation of E-cadherin expression by VHL and hypoxia-inducible factor. Cancer Res. 66, 3567-3575 (2006).
36. Dohadwala M, Yang SC, Luo J et al.: Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 66, 5338-5345 (2006).
37. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. 7, 415-428 (2007).
38. Huang JQ, Sridhar S, Chen Y, Hunt RH: Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114, 1169-1179 (1998).
39. Wang C, Yuan Y, Hunt RH: The association between Helicobacter pylori infection and early gastric cancer: a meta-analysis. Am. J. Gastroenterol. 102, 1789-1798 (2007).
40. Maekita T, Nakazawa K, Mihara M et al.: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 12, 989-995 (2006).
41. Park JH, Kim TY, Jong HS et al.: Gastric epithelial reactive oxygen species prevent normoxic degradation of hypoxia-inducible factor-1α in gastric cancer cells. Clin. Cancer Res. 9, 433-440 (2003).
42. Moles JP, Watt FM: The epidermal stem cell compartment: variation in expression levels of E-cadherin and catenins within the basal layer of human epidermis, J. Histochem. Cytochem. 45, 867-874 (1997).
43. Escaffit F, Perreault N, Jean D et al.: Repressed E-cadherin expression in the lower crypt of human small intestine: a cell marker of functional relevance. Exp. Cell Res. 302, 206-220 (2005).
44. Capaldo CT, Macara IG: Depletion of E-cadherin disrupts establishment but not maintenance of cell junctions in Madin-Darby canine kidney epithelial cells. Mol. Biol. Cell 18, 189-200 (2007).
45. Drubin DG, Nelson WJ: Origins of cell polarity. Cell 84, 335-344 (1996).
46. Nejsum LN, Nelson WJ: A molecular mechanism directly linking E-cadherin adhesion to initiation of epithelial cell surface polarity. J. Cell Biol. 178, 323-335 (2007).
47. Rappaport R: Establishment of the mechanism of cytokinesis in animal cells. Int. Rev. Cytol. 105, 245-281 (1986).
48. Lechler T, Fuchs E: Asymmetric cell divisions promote stratification and differentiation of mammalian skin. Nature 437, 275-280 (2005).
49. Reinsch S, Karsenti E: Orientation of spindle axis and distribution of plasma membrane proteins during cell division in polarized MDCKII cells. J Cell Biol. 126, 1509-1526 (1994).
50. Lu B, Roegiers F, Jan LY, Jan YN: Adherens junctions inhibit asymmetric division in the Drosopbila epithelium. Nature 409, 522-525 (2001).
51. Jefford CE, Irminger-Finger I: Mechanisms of chromosome instability in cancers. Crit. Rev. Oncol. Hematol. 59, 1-14 (2006).
52. Lee CY, Wilkinson BD, Siegrist SE, Wharton RP, Doe CQ: Brat is a Miranda cargo protein that promotes neuronal differentiation and inhibits neuroblast self-renewal. Dev. Cell 10, 441-449 (2006).
53. Betschinger J, Mechtler K, Knoblich JA: Asymmetric segregation of the tumor suppressor brat regulates self-renewal in Drosophila neural stem cells. Cell 124, 1241-1253 (2006).
54. Wodarz A, Gonzalez C: Connecting cancer to the asymmetric division of stem cells. Cell 124, 1121-1123 (2006).
55. Caussinus E, Gonzalez C: Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster Nat. Genet. 37, 1125-1129 (2005).
56. Blider D: Epithelial polarity and proliferation control: links from the Drosophila neoplastic tumor suppressors. Genes Dev. 18, 1909-1925 (2004).
57. Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284 (2007).
58. Prince ME, Sivanandan R, Kaczorowski A et al.: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl Acad Sci. USA 104, 973-978 (2007).
59. Li C, Heidt DG, Dalerba P et al.: Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037 (2007).
60. Singh SK, Hawkins C, Clarke ID et al.: Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
61. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
62. Dalerba P, Dylla SJ, Park IK et al.: Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl Acad. Sci. USA 104, 10158-10163 (2007).
63. Issa JP: DNA methylation as a therapeutic target in cancer. Clin. Cancer Res. 13, 1634-1637 (2007).
64. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF: Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43-47 (2004).
65. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128, 683-692 (2007).
66. Sonneman J, Gange J, Pilz S et al.: Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6, 183 (2006).
67. Kumar KS, Sonnemann J, Hong Le TT et al.: Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma. Anticancer Res. 27, 465-470 (2007).
68. Kim BS, Bae E, Kim YJ et al.: Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia. Anticancer Drugs 18, 641-647 (2007).
69. Wischnewski F. Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol. Cancer Res. 4, 339-349 (2006).
70. Karpf AR: A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1, 116-120 (2006).
71. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5, 37-50 (2006).
72. Yuecheng Y, Hongmei L, Xiaoyan X: Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis 23, 65-74 (2006).
73. Nam JS, Ino Y, Kanai Y, Sakamoto M, Hirohashi S: 5-aza-2′-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin. Exp. Metastasis 21, 49-56 (2004).
74. Si HX, Tsao SW, Lam KY et al.: E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett. 173, 71-78 (2001).
75. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769-784 (2006).
76. Wu Y, Starzinski-Powitz A, Guo SW: Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells. Reprod. Sci. 14, 374-382 (2007).
77. Yoshikawa M, Hishikawa K, Marumo T, Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18, 58-65 (2007).
78. Kumagai T, Wakimoto N, Yin D et al.: Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int. J. Cancer 121, 656-665 (2007).
79. Takai N, Desmond JC, Kumagai T et al.: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 10, 1141-1149 (2004).
80. Ueda T, Takai N, Nishida M, Nasu K, Narahara H: Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int. J. Mol. Med. 19, 301-308 (2007).
81. Butt AJ, Hague A, Paraskeva C: Butyrate- but not TGFβ1-induced apoptosis of colorectal adenoma cells is associated with increased expression of the differentiation markers E-cadherin and alkaline phosphatase. Cell Death Differ. 4, 725-732 (1997).
82. Barshishat M, Polak-Charcon S, Schwartz B: Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells. Br. J. Cancer 82, 195-203 (2000).
83. Davie JR: Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133, S2485-S2493 (2003).
84. Bialer M, Yagen B: Valproic acid: second generation. Neurotherapeutics 4, 130-137 (2007).
85. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103-107 (1999).